INTERNATIONAL JOURNAL IN PHARMACEUTICAL SCIENCES

Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

A Comprehensive Review of Pharmacological Interventions for Chronic Pain

Abel sabu[1], Viresh. k. chandur[2], A R Shabaraya[3]

Department of Pharmacy Practice, Srinivas College of Pharmacy, Mangalore-574143 Karnataka, India

ARTICLE INFO

Received: 20 Nov 2023
Accepted: 22 Nov 2023
Published: 26 Nov 2023
Keywords:
Chronic Pain
DOI:
10.5281/zenodo.10207390

ABSTRACT

Chronic pain is a highly prevalent condition that can have a significant impact on an individual's quality of life. Pharmacological interventions are one of the mainstays of chronic pain management, but their efficacy, safety, and tolerability vary widely. This review article provides a comprehensive overview of the pharmacological interventions available for chronic pain management, including non-opioid analgesics, opioids, antidepressants, anticonvulsants, and topical agents. The article covers the mechanisms of action, efficacy, safety, and adverse effects of these interventions, as well as current guidelines and recommendations for their use in clinical practice. The review synthesizes the available evidence to provide healthcare providers with a valuable resource to guide their decision-making in the management of chronic pain.

INTRODUCTION

Chronic pain is generally defined as any continuous or recurrent pain lasting more than 12 weeks, or pain that persists beyond the normal expected time for tissue healing; causes may be post injury, disease-related or idiopathic. Prevalence rates for idiopathic pain range substantially in community surveys (eg, headache: 8–83%; abdominal pain: 4–53%; back pain: 14–24%; musculoskeletal pain: 4–40%), they are generally higher in girls and increase with age [1]. However, once pain evolves into a chronic state, its adaptive nature is superimposed by negative sequelae that have a massive effect on both the individual and society. Chronic pain is recognised by WHO as a disease and is one of the most prevalent diseases worldwide, leading to substantial disability and enormous societal costs[2].

Chronic pain is a common condition in primary care and one that challenges both the distinction between mind and body and the concept of cure being the goal of medical intervention [3]. Non - opioid analgesics, opioids, antidepressants, anticonvulsants, and topical agents are among the most commonly used pharmacological interventions for chronic pain. While these interventions can provide pain relief, their use is

***Corresponding Author:** Abel sabu
Address: *Department of Pharmacy Practice, Srinivas College of Pharmacy, Mangalore-574143 Karnataka, India*
Email ✉: abelsabusam@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

often associated with adverse effects, such as gastrointestinal upset, sedation, and respiratory depression.

Given the challenges associated with the use of pharmacological interventions for chronic pain, there is a need for a comprehensive review of the available pharmacological interventions, their mechanisms of action, efficacy, safety, and adverse effects. Such a review can help healthcare providers make informed decisions regarding the pharmacological management of chronic pain and improve patient outcomes. Therefore, this review article aims to provide a comprehensive overview of the pharmacological interventions available for chronic pain management. It will cover the various classes of medications, their mechanisms of action, efficacy and safety. By synthesizing the available evidence, this review article aims to provide healthcare providers with a valuable resource to guide their decision-making in the management of chronic pain.

2.TYPES OF CHRONIC PAIN:

2.1 NEUROPATHIC PAIN:

Neuropathic pain refers to pain that originates from pathology of the nervous system. Neuropathic pain is distinguished from other pain conditions where the pain generator begins with disease of non-neural tissues. These non-neuropathic pain entities are said to be nociceptive and include conditions such as osteoarthitis and inflammatory pain. By definition, neuropathic pain originates from a lesion of the nervous system[4]. Many patients with neuropathic pain exhibit persistent or paroxysmal pain that is independent of a stimulus. This stimulus-independent pain can be shooting, lancinating, or burning and may depend on activity in the sympathetic nervous system.

2.2 MUSCULOSKELETAL PAIN:

Chronic musculoskeletal pain is defined as a pain perceived in musculoskeletal tissues that lasts or recurs for more than 3months, and is characterized by significant functional disability and emotional distress. Pain is categorized as primary chronic pain if it cannot be directly attributed to a known disease or damage process, or as secondary if it is caused by a disease or process that directly affects the bones, joints, muscles, and/or related soft tissues[5]. Musculoskeletal (MSK) pain has a major impact on people's quality of life. Chronic MSK pain causes sleep interruption, fatigue, depressed mood, activity limitations and participation restrictions. The impact of MSK pain is influenced by contextual factors, including comorbidity, arthritis coping efficacy and access to MSK care.

2.3 INFLAMMATORY PAIN:

Pain produced by intense, potentially harmful stimuli is an important early warning sign that helps avoid tissue damage. This type of pain is known as nociceptive pain. .Inflammatory pain develops when the sensitivity of the nociceptive system increases after the tissue integrity is disrupted by trauma, heat, infection, toxins, inadequate immune responses, tumors or other insults[6].

2.4 CANCER RELATED PAIN:

Pain is the commonest symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment. Between 33% and 40% of cancer survivors (persons with cancer whose curative treatment was completed) suffer from chronic pain [7]. The prevalence of uncontrolled cancer-related pain in outpatient populations remains high despite claims that pain can be relieved in more than 90% of cases . Despite this potential, 70% of patients who die from cancer will have unrelieved pain. Pain is the most persistent and incapacitating symptom, as well as the most distressing symptom experienced by cancer patients [8].

3.PHARMACOLOGICAL APPROACHES:

During the past decade there has been an explosion of knowledge regarding the underlying

neuroanatomical pathways and the neurophysiological mechanisms involved in the complex experience of pain and the contributions of psychosocial factors to the pain experience, patients' responses to nociceptive stimulation, and treatment. As a consequence, there have been significant advances in the development of pharmacological, surgical, neuroaugmentative, and psychological treatment modalities[9].

3.1 NON-OPIOID MEDICATIONS:

Non-opioid medications are being explored as alternatives for chronic pain management. Several studies have investigated the effectiveness of non-opioid substances in relieving pain. Marchesi et al. reviewed the pain-relieving effects of various non-drug substances, including vitamins, alpha lipoic acid, and curcumin [10]. Bergman et al. compared different pain control regimens after sinonasal surgery and found that both meloxicam and oxycodone with budesonide rinses were more effective at controlling pain than oxycodone alone [11]. Elphinston et al. examined the association between pain catastrophizing and prescription opioid use, and found that beliefs about the appropriateness of pain medicines mediated this association [12]. Nichols et al. conducted a qualitative synthesis and identified themes related to the experience of taking opioid medication for chronic non-malignant pain, including the challenge of tapering or withdrawal [13]. Pope and Deer discussed the current guidelines for safe prescribing of opioids and the focus on minimizing opioid initiation [14]. These studies highlight the potential of non-opioid medications and the need for personalized pain management approaches

3.1.1 NON STEROIDAL ANTI INFLAMMATORY DRUGS:

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for the management of chronic pain, including chronic low back pain (LBP) and postoperative pain. However, there is ongoing debate regarding their efficacy and safety. Several clinical studies have shown controversial results, and the most effective and safe class of drugs has not yet been clarified [15]. The use of NSAIDs as part of multimodal analgesia has been suggested to reduce the risk of long-term use and prevent the development of chronic pain syndrome [16]. NSAIDs are recommended as first-line analgesics for low back pain, sciatica, and osteoarthritis, and are widely prescribed for musculoskeletal pain [17]. NSAIDs exert their role mainly through inhibition of cyclooxygenase and prostaglandin synthesis [18].

3.1.2 ANTIDEPRESSANTS:

Antidepressants have been studied for their efficacy in treating chronic pain. Research has shown that certain antidepressants, such as amitriptyline, citalopram, duloxetine, fluoxetine, paroxetine, and sertraline, may improve quality of life, pain, sleep, and psychological distress in patients with chronic primary pain [19]. These antidepressants have been recommended by NICE for the management of chronic primary pain [20]. Additionally, a Cochrane Review protocol aims to assess the comparative efficacy and safety of antidepressants for adults with chronic pain, evaluating their impact on pain, mood, physical functioning, sleep quality, and quality of life [21]. Furthermore, a study found that tricyclic antidepressants (TCAs) like amitriptyline and nortriptyline can reduce pain severity and improve disability in chronic low back pain when used routinely for several weeks [22]. It is important to consider comorbid depression when dosing antidepressants for chronic pain relief, as higher serum concentrations of antidepressants have been associated with better pain relief outcomes in patients with comorbid depression [23].

3.1.3 ANTICONVULSANTS:

Anticonvulsants are commonly used for the treatment of chronic pain conditions such as neuropathic pain, trigeminal neuralgia, migraine

headache, and myofascial pain [24]. However, the evidence for the effectiveness of anticonvulsants in reducing pain related to complex regional pain syndrome (CRPS) is considered insufficient [25]. Multiple studies have shown that anticonvulsants, including gabapentinoids, are not effective in reducing pain or disability in patients with low back pain or lumbar radicular pain [26]. Despite their widespread use, the evidence supporting the use of antidepressants and anticonvulsants for a wide variety of pain disorders is limited [27].

3.1.4 LOCAL ANAESTHETICS:

Local anaesthetics are commonly used for chronic non-cancer pain (CNCP) injections, but the benefit of adding steroids to local anaesthetics (SLA) is uncertain. A systematic review and meta-analysis of RCTs found that SLA increased the rate of success, but the effect size decreased when two intrathecal injection studies were removed. The differences in pain scores with SLA were not clinically meaningful. No differences were observed in other outcomes or adverse events. Meta-regression showed no significant association with steroid dose or length of follow-up and pain relief. The addition of corticosteroids to local anaesthetics has only small benefits and a potential for harm. Injection of local anaesthetic alone could be therapeutic. A shared decision based on patient preferences should be considered. [28] Local anaesthetic systemic toxicity (LAST) is a serious complication that can occur with the administration of local anaesthetics. Intralipid emulsion (ILE) infusions have been successfully used to reverse local anaesthetic-induced cardiotoxicity. ILE infusion has been incorporated into safety guidelines for managing LAST. [29] Local anaesthetics are widely used for regional anesthesia and pain management.

3.1.5 MUSCLE RELAXANTS:

Muscle relaxants are commonly used for the treatment of chronic pain. In the context of cerebral palsy (CP), oral muscle relaxants such as baclofen, dantrolene, and diazepam have been used, but the evidence supporting their efficacy is limited and mixed. Botulinum toxin injections are also used but require repeated needle sticks. More recent options include cyclobenzaprine and tizanidine, although further evidence is needed to support their use . Muscle relaxants, including benzodiazepines and non-benzodiazepines, have gained widespread clinical acceptance as adjuvants in the management of patients with rheumatoid arthritis (RA) and chronic musculoskeletal pain [30]. Skeletal muscle relaxants are frequently prescribed for low back pain and other musculoskeletal pain, but there is no clear evidence to show superiority of one muscle relaxant over another in managing acute low back pain, and most guidelines and current evidence support short-term use [31]. Muscle relaxants can have a clinically significant role in the treatment of chronic muscle pain, but their use should be carefully considered due to possible serious side effects [32].

3.2 OPIOID MEDICATIONS:

Opioid medications are frequently prescribed for the treatment of chronic pain, despite safety concerns and limited evidence for their efficacy [33]. However, current guidelines discourage the use of opioids for chronic pain management [34]. Non-opioid medications, such as NSAIDs, antidepressants, cannabinoids, and ketamine, are also commonly used for pain treatment [35]. In the acute and subacute phases of low back pain, the goal of pharmacological treatment is to enable patients to stay active, with NSAIDs being the most studied and commonly used medication . Opioids can be effective in treating pain but can also be highly addictive, leading to opioid use disorders (OUD). Treatment options for OUD have advanced, and prescribers are encouraged to be capable of treating OUD [36].

3.2.1 MECHANISM OF ACTION:

Opioid medications for chronic pain work by interacting with specific receptors in the central nervous system (CNS) and periphery, mimicking the effects of endogenous opioid peptides. These receptors modulate nociceptive transmission and are also involved in the regulation of gastrointestinal, endocrine, and autonomic functions [37]. The analgesic effects of opioids are potent and long-lasting, primarily due to the inhibition of nociceptive signals in the spinal cord [38]. However, side effects are mainly mediated by the activation of opioid receptors in the brain and brain stem [39]. Prescribing opioids for chronic pain requires careful consideration of individual drug pharmacokinetics and pharmacodynamics, as well as their actions across different physiological systems and patient factors that influence drug efficacy .Additionally, chronic pain management often involves the use of multiple agents to take advantage of synergistic mechanisms of action, while considering potential drug-drug interactions. [40].

3.2.2 OPIOID RECEPCTOR AGONISTS:

Opioid receptor agonists have been studied for their potential in treating chronic pain. Combination therapies with other drugs have been explored to reduce side effects. One study found that the combination of the mu-opioid agonist morphine and the selective CB2 agonist JWH015 showed synergistic inhibition of preclinical pain while reducing opioid-induced side effects [41]. Another study focused on developing G protein-biased mu-opioid receptor (MOR) agonists as analgesics with fewer side effects. Novel derivatives of PZM21 were synthesized and showed more potent analgesic activities and bias toward G protein signaling [42]. Additionally, delta opioid receptor (DOPr) agonists have emerged as a promising target for pain therapy due to their potential to avoid unwanted effects associated with mu opioid receptor (MOPr) agonists [43]. These studies suggest that opioid receptor agonists, including MOR and DOPr agonists, hold promise for the treatment of chronic pain.

3.2.3 OPIOID RECEPTOR PARTIAL AGONISTS:

Opioid receptor partial agonists have been studied as potential treatments for chronic pain. The use of mu-opioid receptor (MOR) agonists, such as morphine, in combination with other agents, such as CB2 agonists, has shown promise in preclinical models for inhibiting chronic pain while reducing unwanted side effects [44]. G protein-biased MOR agonists, like PZM21 derivatives, have also been developed as analgesics with fewer adverse side effects [45]. Additionally, delta opioid receptor (DOPr) agonists have emerged as a promising target for pain therapy, as they may avoid the unwanted effects commonly observed with clinically used MOR agonists [46]. However, the effectiveness of opioid prescription for chronic non-cancer pain (CNCP) is debated, with limited evidence of pain and function improvement and frequent adverse effects [47]. Overall, opioid receptor partial agonists, including MOR and DOPr agonists, show potential for the treatment of chronic pain, but further research is needed to determine their efficacy and safety in clinical settings.

3.2.4 OPIOID RECEPTOR ANTAGONIST:

Opioid receptor antagonists have been studied for their potential use in chronic pain management. One study investigated the use of peripherally acting μ-opioid receptor antagonists (PAMORAs) for opioid-induced constipation (OIC) in patients with advanced illness or chronic noncancer pain. Methylnaltrexone, a PAMORA, was found to be effective in treating refractory OIC when traditional laxatives were not effective [48]. Another study explored the development of novel bifunctional hybrid compounds that combine opioid agonists with melanocortin type 4 (MC4) receptor antagonists. These compounds showed promising analgesic effects in mouse models of

acute and neuropathic pain, suggesting their potential use in neuropathic pain treatment [49]. Additionally, the combination of prolonged release (PR) oxycodone and naloxone was found to reduce constipation in patients with chronic noncancer pain. This combination product has been designated as a tamper-resistant opioid and has demonstrated equivalent analgesia to PR oxycodone at certain doses [50]. Overall, opioid receptor antagonists show potential for managing chronic pain and its associated side effects.

3.3 ADJUVANT MEDICATIONS:

Adjuvant medications are commonly used in the treatment of chronic pain. These medications, such as tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), and gabapentinoids, are considered first-line treatments for neuropathic pain [51]. However, the use of adjuvant medications can have potential interactions and side effects. For example, opioids, which are often used in conjunction with adjuvant medications, have been associated with hypotension [52]. Additionally, the use of gabapentinoids has been found to be associated with an increased risk of dizziness [53]. It is important for healthcare providers to carefully consider the potential interactions and side effects of adjuvant medications when prescribing them for chronic pain management. Further research is needed to better understand the efficacy and safety of these medications in the treatment of chronic pain [54].

3.3.1 CORTICOSTEROIDS:

Corticosteroids have been used in the management of chronic pain conditions such as chronic non-cancer pain (CNCP), chronic spinal pain, osteoarthritis pain, and pain flare induced by radiotherapy for bone metastases. However, the benefit of adding steroids to local anesthetics for CNCP injections is uncertain, as the effect size is small and there is a potential for harm [55]. Corticosteroids remain important considerations in the multimodal pain management of chronic spinal pain and osteoarthritis pain, although new treatment options such as PRP and hyaluronic acid are emerging [56]. Prophylactic corticosteroids have shown efficacy in preventing pain flare in patients undergoing radiotherapy for bone metastases, with no severe toxicity reported [57]. Extended perioperative corticosteroids after transoral robotic surgery (TORS) may allow earlier improvement in diet consistency and decreased length of hospital stay, although the effect on postoperative pain appears minimal [58].

3.3.2 NMDA RECEPTOR ANTAGONISTS:

NMDA receptor antagonists, such as ketamine, have been studied for their potential benefits in chronic non-cancer pain management. Ketamine appears to hold the most promise and may be particularly valuable in perioperative pain management [59]. Other NMDA receptor antagonists, including memantine, dextromethorphan, and amantadine, have also been explored for their analgesic properties . These agents have shown potential in reducing opioid requirements and improving perioperative and chronic pain relief [60]. However, further research is needed to determine the optimal dosage and administration regimens for NMDA receptor antagonists [61]. Overall, NMDA receptor antagonists have demonstrated potential as a pharmacological strategy for chronic pain management, but more studies are required to establish their efficacy and safety [62] .

3.3.3 BENZODIAZEPINES:

Benzodiazepines are commonly prescribed for chronic pain, but their use in this context is controversial and lacks sufficient evidence. The combination of opioids and benzodiazepines is correlated with overdose and overdose death, and eliminating benzodiazepines could decrease overdoses by over 15% [63]. Benzodiazepine receptor agonists (BZRAs) have shown analgesic benefit for certain pain conditions, but their use

should be limited to specific cases and for short periods of time [64]. Benzodiazepine use in chronic pain patients has been associated with worse outcomes in mood and functioning, and there is no evidence of benefit in terms of pain relief or disability reduction [65]. Co-prescribing opioids and benzodiazepines increases the risk of adverse outcomes, including overdose and death [66].

3.3.4 CANNABINOIDS:

Cannabinoids have shown potential for the treatment of chronic pain, with evidence suggesting their effectiveness in reducing pain scores and improving sleep [67] . Inhaled cannabis has consistently demonstrated analgesic effects for chronic non-cancer pain, while oral cannabinoids have shown benefits for certain aspects of chronic pain, such as sleep and general quality of life, but not for acute postoperative pain, abdominal chronic pain, or rheumatoid pain [68] . Adverse effects of cannabinoids are generally mild to moderate and well tolerated, with rare incidence of serious adverse events . However, the effect sizes of cannabinoids on pain reduction are small, and further research is needed to improve bioavailability and explore other aspects of pain management in patients using cannabinoids .

4.EFFICACY AND SAFETY CONSIDERATION:

Chronic pain is a complex condition that requires consideration of both efficacy and safety. Duloxetine, an antidepressant, has been shown to be effective in treating chronic musculoskeletal pain (CMP) and can improve mood and pain levels simultaneously [69]. Cannabidiol (CBD) has also shown potential for chronic pain relief, sleep improvement, and quality of life enhancement, although more clinical trials are needed to establish its significance [70]. Strong opioids have been increasingly prescribed for chronic non-cancer pain (CNCP), but their long-term use is controversial due to uncertainties and potential risks, including adverse events, opioid abuse/dependence, and increased mortality [71]. In the treatment of chronic low back pain (CLBP), opioids have limited efficacy and safety concerns, and current guidelines discourage their use, recommending alternative treatments such as exercise therapy and non-opioid medications [72].

4.1 EFFECTIVENESS OF DIFFERENT PHARMACOLOGICAL INTERVENTIONS:

Psychological interventions have been found to have a significant impact on pain relief, quality of life, depression, and stress in individuals with chronic pain [73]. Cognitive behavioral therapy is ranked as the most effective psychological intervention for chronic pain, followed by acceptance and commitment therapy and mindfulness methods . Pharmacotherapies such as bisphosphonates and denosumab are commonly prescribed to mitigate skeletal disease activity and pain in fibrous dysplasia and McCune-Albright Syndrome, but there is a lack of rigorously validated analgesic strategies for these conditions [74]. Percutaneous and minimally invasive interventions, such as radiofrequency ablation and steroid injections, have shown varying levels of effectiveness in improving pain and disability in chronic low back pain [75].

4.2 INDIVIDUALIZED TREATMENT APPROACHES:

Individualized treatment approaches for chronic pain are important in managing this condition effectively. Psychotherapeutic assistance, such as cognitive behavioral therapy and mindfulness therapy, has been shown to be effective in managing chronic musculoskeletal pain [76]. Nonopioid medication and nonpharmacologic pain management are recommended as first-line treatments for chronic pain, according to the CDC guideline [77]. Interventional pain treatments, including procedures for spinal pain, neuropathic pain, and musculoskeletal pain, can be used for both diagnosis and treatment . Rehabilitation medicine offers strategies to reduce

musculoskeletal pain, alleviate movement-related pain, and optimize patients' function despite persistent pain [78]. Implementing individualized, comprehensive pain management programs that incorporate these approaches can empower patients and limit pain associated with mobility and daily activities [79].

5. EMERGING THERAPIES AND FUTURE DIRECTIONS:

Chronic pain is a complex condition that affects millions of people worldwide and can significantly impact their quality of life. Traditional treatment for chronic pain, such as medications, physical therapy and surgery have limitations in terms of effectiveness and potential side effects. However, there are several emerging therapies and future directions that hold promise in the management of chronic pain.

5.1 NOVEL DRUG TARGETS AND APPROACHES:

Novel drug targets and approaches for chronic pain include targeting intracellular changes caused by repeated stimulus application, or neuronal priming, along the pathway for neural transmission of pain [80]. Other potential targets include adrenergic, cannabinoid, P2X3 and P2X7, NMDA, serotonin, and sigma receptors, as well as voltage-gated sodium channels and enzymes such as soluble epoxide hydrolase, sepiapterin reductase, and MAGL/FAAH [81]. Additionally, individualized diagnostic technologies, improvement of existing therapies, and expansion of current pharmacological treatments are being explored to broaden pharmacological options for persistent pain management [82]. The development of novel analgesics that do not involve the mu opioid receptor but have high analgesic potency and low risk of adverse effects, particularly no abuse liability, is also a focus [83].

5.2 PERSONALIZED MEDICINE AND BIOMARKERS:

Personalized medicine and biomarkers for chronic pain are areas of active research. The kynurenine pathway, which is responsible for the metabolization of tryptophan, has been identified as a potential source of biomarkers for chronic pain [84]. However, it is unlikely that a single test will encompass the variety of chronic pain phenotypes, indicating the need for further research in biomarker development [85]. Currently, there are no identified biological markers for chronic pain, despite its prevalence and impact on patient care . In the case of knee osteoarthritis, deep learning models have been used to explore associations between imaging biomarkers and chronic knee pain, leading to the development of a novel biomarker definition for cartilage thickness [86]. Brain imaging studies have also shown promise in identifying biomarkers for chronic pain, particularly in understanding the role of the limbic brain circuitry and dopaminergic signaling [87]. These findings suggest that biomarkers for chronic pain are on the horizon, offering potential advancements in personalized medicine.

5.3 NON-PHARMACOLOGICAL INTERVENTIONS:

Non-pharmacological interventions have been studied for chronic pain management. Psychological interventions, such as cognitive behavioral therapy, acceptance and commitment therapy, and mindfulness, have shown effectiveness in relieving pain, reducing stress and depression, and improving the quality of life [88]. Non-pharmacological interventions for chronic obstructive pulmonary disease (COPD)-related pain have shown mixed results, with some interventions reporting minimal clinical differences in pain outcomes [89]. Percutaneous and minimally invasive interventions, such as radiofrequency ablation and biological therapy, have been found to provide significant improvements in pain and disability for chronic

low back pain [90]. Perioperative psychological interventions have shown promise in reducing the incidence of chronic post-surgical pain, but further research is needed to determine the most effective type, intensity, duration, and timing of interventions [91].

6.CONCLUSION:

Chronic pain is a complex and debilitating condition that affects a large proportion of the global population. Pharmacological interventions are one of the mainstays of chronic pain management, but their efficacy, safety, and tolerability vary widely. This review article has provided a comprehensive overview of the pharmacological interventions available for chronic pain management, including non-opioid analgesics, opioids, antidepressants, anticonvulsants, and topical agents. The article has covered the mechanisms of action, efficacy, safety, and adverse effects of these interventions, as well as current guidelines and recommendations for their use in clinical practice. By synthesizing the available evidence, this review article aims to provide healthcare providers with a valuable resource to guide their decision-making in the management of chronic pain.

REFERENCES

1. Rajapakse D, Liossi C, Howard RF. Presentation and management of chronic pain. Archives of Disease in Childhood. 2014;99(5):474–80. doi:10.1136/archdischild-2013-304207
2. Nijs J, George SZ, Clauw DJ, Fernández-de-las-Peñas C, Kosek E, Ickmans K, et al. Central sensitisation in chronic pain conditions: Latest discoveries and their potential for precision medicine. The Lancet Rheumatology. 2021;3(5). doi:10.1016/s2665-9913(21)00032-1
3. Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: A Review. Current Psychiatry Reports. 2016;18(2). doi:10.1007/s11920-015-0659-9
4. 4.Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77–92. doi:10.1016/j.neuron.2006.09.021
5. Puntillo F, Giglio M, Paladini A, Perchiazzi G, Viswanath O, Urits I, et al. Pathophysiology of musculoskeletal pain: A narrative review. Therapeutic Advances in Musculoskeletal Disease. 2021;13. doi:10.1177/1759720x21995067
6. Chen L, Yang G, Grosser T. Prostanoids and Inflammatory Pain. Prostaglandins & Other Lipid Mediators. 2013;104–105:58–66. doi:10.1016/j.prostaglandins.2012.08.006
7. Bennett MI, Eisenberg E, Ahmedzai SH, Bhaskar A, O'Brien T, Mercadante S, et al. Standards for the management of cancer-related pain across Europe—a position paper from the EFIC Task Force on Cancer Pain. European Journal of Pain. 2019;23(4):660–8. doi:10.1002/ejp.1346
8. Vallerand AH, Templin T, Hasenau SM, Riley-Doucet C. Factors that affect functional status in patients with cancer-related pain. Pain. 2007;132(1):82–90. doi:10.1016/j.pain.2007.01.029
9. Turk DC, Okifuji A. Psychological factors in chronic pain: Evolution and revolution. Journal of Consulting and Clinical Psychology. 2002;70(3):678–90. doi:10.1037/0022-006x.70.3.678
10. Marchesi N, Govoni S, Allegri M. Non-drug pain relievers active on non-opioid pain mechanisms. Pain Practice. 2021;22(2):255–75. doi:10.1111/papr.13073
11. Bergman JE, Casiano RR, Perez AB, Mantero AM, Levine CG. Opiate vs non-opiate prescription medication for pain control after endoscopic sinus surgery for chronic rhinosinusitis. American Journal of

Otolaryngology. 2022;43(1):103214. doi:10.1016/j.amjoto.2021.103214

12. Elphinston RA, Sullivan MJL, Sterling M, Connor JP, Baranoff JA, Tan D, et al. Pain medication beliefs mediate the relationship between pain catastrophizing and opioid prescription use in patients with chronic non-cancer pain. The Journal of Pain. 2022;23(3):379–89. doi:10.1016/j.jpain.2021.08.009
13. Nichols VP, Toye F, Eldabe S, Sandhu HK, Underwood M, Seers K. Experiences of people taking opioid medication for chronic non-malignant pain: A qualitative evidence synthesis using meta-ethnography. BMJ Open. 2020;10(2). doi:10.1136/bmjopen-2019-032988
14. Pope JE, Deer TR. Opioids for chronic non-cancer pain. Deer's Treatment of Pain. 2019;231–2. doi:10.1007/978-3-030-12281-2_28
15. Migliorini F, Maffulli N, Eschweiler J, Tingart M, Baroncini A. Non-steroidal anti-inflammatory drugs and gabapentinoids for chronic lumbar pain: A bayesian network meta-analysis of randomized controlled trials. British Medical Bulletin. 2021;138(1):85–95. doi:10.1093/bmb/ldab003
16. Hladkykh F. Multimodal analgesia: Polypharmacy in pain relief or rational use of non-steroidal anti-inflammatory drugs to prevent pain chronicity. Path of Science. 2020;6(7):4008–18. doi:10.22178/pos.60-5
17. Machado GC, Abdel-Shaheed C, Underwood M, Day RO. Non-steroidal anti-inflammatory drugs (nsaids) for musculoskeletal pain. BMJ. 2021; doi:10.1136/bmj.n104
18. Dara P, Talabi O, Iderapalli M. Non-steroidal anti-inflammatory drugs can interact with lithium and antidepressants. BMJ. 2021; doi:10.1136/bmj.n679
19. Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, et al. Antidepressants for pain management in adults with chronic pain: A network meta-analysis. Cochrane Database of Systematic Reviews. 2021; doi:10.1002/14651858.cd014682
20. Kmietowicz Z. Offer exercise, therapy, acupuncture, or antidepressants for chronic primary pain, says nice. BMJ. 2021; doi:10.1136/bmj.n907
21. Brown M. New nice guideline: Antidepressants and chronic pain — chicken or egg? British Journal of General Practice. 2021;71(708):320–320. doi:10.3399/bjgp21x716345
22. Scherf-Clavel M, Breisinger S, Fischer M, Deckert J, Unterecker S, Rittner HL. Therapeutic drug monitoring of antidepressants for the treatment of chronic musculoskeletal pain with and without depression. Therapeutic Drug Monitoring. 2020;42(6):893–901. doi:10.1097/ftd.0000000000000783
23. Ilmanita D, Hidayati HB. Tricyclic antidepressants in chronic low back pain : A Review. Journal of Islamic Pharmacy. 2020;4(2):21. doi:10.18860/jip.v4i2.8217
24. Li CT, Watson JC. Anticonvulsants in the treatment of pain. Deer's Treatment of Pain. 2019;149–61. doi:10.1007/978-3-030-12281-2_19
25. Javed S, Abdi S. Use of anticonvulsants and antidepressants for treatment of complex regional pain syndrome: A literature review. Pain Management. 2021;11(2):189–99. doi:10.2217/pmt-2020-0060
26. Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: A systematic review and meta-analysis. Canadian Medical

Association Journal. 2018;190(26). doi:10.1503/cmaj.171333

27. Okafor C, Aquino M. Antidepressants and anticonvulsants. Academic Pain Medicine. 2019;75–9. doi:10.1007/978-3-030-18005-8_14
28. Shanthanna H, Busse J, Wang L, Kaushal A, Harsha P, Suzumura EA, et al. Addition of corticosteroids to local anaesthetics for chronic non-cancer pain injections: A systematic review and meta-analysis of Randomised Controlled Trials. British Journal of Anaesthesia. 2020;125(5):779–801. doi:10.1016/j.bja.2020.06.062
29. Sheppard HN, Anandampillai R. Systemic toxic effects of local anaesthetics. Anaesthesia & Intensive Care Medicine. 2019;20(4):215–8. doi:10.1016/j.mpaic.2019.01.022
30. Chang WJ. Muscle relaxants for acute and chronic pain. Physical Medicine and Rehabilitation Clinics of North America. 2020;31(2):245–54. doi:10.1016/j.pmr.2020.01.005
31. Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2011; doi:10.1002/14651858.cd008922
32. Travnicek KD. Antispasmodics and muscle relaxants. Deer's Treatment of Pain. 2019;181–9. doi:10.1007/978-3-030-12281-2_22
33. Oldfield BJ, Fuller WS, Becker WC. Opioids are not better than non-opioid pain medications for chronic back, hip, or knee pain. Journal of General Internal Medicine. 2019;34(9):1854–6. doi:10.1007/s11606-019-05016-4
34. Dekeseredy P, Sedney CL, Razzaq B, Haggerty T, Brownstein HH. Tweeting stigma: An exploration of Twitter discourse regarding medications used for both opioid use disorder and chronic pain. Journal of Drug Issues. 2021;51(2):340–57. doi:10.1177/0022042620986508
35. Phillips C, Contreras E, Oswald J. NSAIDs, opioids, and beyond. Pain Management - Practices, Novel Therapies and Bioactives. 2021; doi:10.5772/intechopen.93843
36. Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. Journal of the Neurological Sciences. 2020;411:116728. doi:10.1016/j.jns.2020.116728
37. Oesterle TS, Kolla BP, Rummans TA, Gold MS. Medication-assisted therapies for opioid use disorders in patients with chronic pain. Journal of the Neurological Sciences. 2020;411:116728. doi:10.1016/j.jns.2020.116728
38. Asmar A. Psychotropic medications for chronic pain. Current Psychiatry. 2022;21(11). doi:10.12788/cp.0304
39. Vázquez M, Fagiolino P. Pharmacotherapy of chronic pain. Pain Relief - From Analgesics to Alternative Therapies. 2017; doi:10.5772/66444
40. Koppert W. Opioid-induzierte hyperalgesie. Der Anaesthesist. 2004;53(5):455–66. doi:10.1007/s00101-004-0669-1
41. Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, et al. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology. 2017;116:59–70. doi:10.1016/j.neuropharm.2016.12.008
42. Ma M, Li X, Tong K, Cheng J, Yu Z, Ren F, et al. Discovery of biased mu-opioid receptor agonists for the treatment of pain. ChemMedChem. 2019;15(1):155–61. doi:10.1002/cmdc.201900575
43. Berthiaume S, Abdallah K, Blais V, Gendron L. Alleviating pain with Delta opioid receptor

agonists: Evidence from experimental models. Journal of Neural Transmission. 2020;127(4):661–72. doi:10.1007/s00702-020-02172-4

44. Grenald SA, Young MA, Wang Y, Ossipov MH, Ibrahim MM, Largent-Milnes TM, et al. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists. Neuropharmacology. 2017;116:59–70. doi:10.1016/j.neuropharm.2016.12.008
45. Salvemini D, Jacobson KA. Highly selective A3 adenosine receptor agonists relieve chronic neuropathic pain. Expert Opinion on Therapeutic Patents. 2017;27(8):967–967. doi:10.1080/13543776.2017.1341018
46. Ma M, Li X Tong K, Cheng J, Yu Z, Ren F, et al. Discovery of biased mu-opioid receptor agonists for the treatment of pain. ChemMedChem. 2019;15(1):155–61. doi:10.1002/cmdc.201900575
47. Berthiaume S, Abdallah K, Blais V, Gendron L. Alleviating pain with Delta opioid receptor agonists: Evidence from experimental models. Journal of Neural Transmission. 2020;127(4):661–72. doi:10.1007/s00702-020-02172-4
48. Starnowska-Sokół J, Piotrowska A, Bogacka J, Makuch W, Mika J, Witkowska E, et al. Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of Neuropathic Pain. Neuropharmacology. 2020;178:108232. doi:10.1016/j.neuropharm.2020.108232
49. J. Urtisky, PharmD, BCPS, CPE T. Methylnaltrexone: Peripherally acting μ-opioid receptor antagonist. Journal of the Advanced Practitioner in Oncology. 2019;10(1). doi:10.6004/jadpro.2019.10.1.5
50. Turnaturi R, Chiechio S, Pasquinucci L, Spoto S, Costanzo G, Dichiara M, et al. Novel N-normetazocine derivatives with opioid agonist/sigma-1 receptor antagonist profile as potential analgesics in inflammatory pain. Molecules. 2022;27(16):5135. doi:10.3390/molecules27165135
51. Hasvik E, Gran JM, Haugen AJ, Grøvle L. Strategies to manage auxiliary pain medications in chronic pain trials: A topical review. European Journal of Clinical Pharmacology. 2022;78(9):1377–84. doi:10.1007/s00228-022-03355-6
52. Urits I, Li N, Berardino K, Artounian KA, Bandi P, Jung JW, et al. The use of antineuropathic medications for the treatment of chronic pain. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):493–506. doi:10.1016/j.bpa.2020.08.007
53. Shen Y, Hincapie-Castillo J, Vouri S, Dewar M, Sumfest J, Goodin A. Prescription patterns of adjuvant pain medications following an opioid supply restriction law. Medical Care. 2022;60(6):432–6. doi:10.1097/mlr.0000000000001719
54. Rivasi G, Menale S, Turrin G, Coscarelli A, Giordano A, Ungar A. The effects of pain and analgesic medications on blood pressure. Current Hypertension Reports. 2022;24(10):385–94. doi:10.1007/s11906-022-01205-5
55. Shanthanna H, Busse J, Wang L, Kaushal A, Harsha P, Suzumura EA, et al. Addition of corticosteroids to local anaesthetics for chronic non-cancer pain injections: A systematic review and meta-analysis of Randomised Controlled Trials. British Journal of Anaesthesia. 2020;125(5):779–801. doi:10.1016/j.bja.2020.06.062
56. Knezevic NN, Jovanovic F, Voronov D, Candido KD. Do corticosteroids still have a place in the treatment of chronic pain? Frontiers in Pharmacology. 2018;9. doi:10.3389/fphar.2018.01229

57. Fabregat C, Almendros S, Navarro-Martin A, Gonzalez J. Pain flare-effect prophylaxis with corticosteroids on bone radiotherapy treatment: A systematic review. Pain Practice. 2019;20(1):101–9. doi:10.1111/papr.12823
58. Clayburgh D, Stott W, Bolognone R, Palmer A, Achim V, Troob S, et al. A randomized controlled trial of corticosteroids for pain after transoral robotic surgery. The Laryngoscope. 2017;127(11):2558–64. doi:10.1002/lary.26625
59. Ferraro MC, Cashin AG, O'Connell NE, Visser EJ, Abdel Shaheed C, Wewege MA, et al. Ketamine and other NMDA receptor antagonists for chronic pain. Cochrane Database of Systematic Reviews. 2023;2023(3). doi:10.1002/14651858.cd015373
60. Kreutzwiser D, Tawfic QA. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs. 2019;33(4):347–74. doi:10.1007/s40263-019-00618-2
61. Kamdar MM. Ketamine and NMDA-receptor antagonists. Deer's Treatment of Pain. 2019;199–204. doi:10.1007/978-3-030-12281-2_24
62. Schroeder C, Schroeder K. NMDA receptor antagonists. Pain. 2019;285–7. doi:10.1007/978-3-319-99124-5_62
63. Peppin JF, Wright SL. Benzodiazepines and pain management. The Benzodiazepines Crisis. 2020;149–59. doi:10.1093/med/9780197517277.003.0009
64. Wright SL. Limited utility for benzodiazepines in Chronic pain management: A narrative review. Advances in Therapy. 2020;37(6):2604–19. doi:10.1007/s12325-020-01354-6
65. Gauntlett-Gilbert J, Gavriloff D, Brook P. Benzodiazepines may be worse than opioids. The Clinical Journal of Pain. 2016;32(4):285–91. doi:10.1097/ajp.0000000000000253
66. Zaman T, Rife TL, Batki SL, Pennington DL. An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines. Substance Abuse. 2018;39(4):441–8. doi:10.1080/08897077.2018.1455163
67. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of Randomized Trials. British Journal of Clinical Pharmacology. 2011;72(5):735–44. doi:10.1111/j.1365-2125.2011.03970.x
68. Lynch ME. Cannabinoids in the management of chronic pain: A Front Line Clinical Perspective. Journal of Basic and Clinical Physiology and Pharmacology. 2015;27(3):189–91. doi:10.1515/jbcpp-2015-0059
69. Ma X, Zhou S, Sun W, Sun J, Li G, Wang L, et al. Efficacy and safety of duloxetine in chronic musculoskeletal pain: A systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2023;24(1). doi:10.1186/s12891-023-06488-6
70. Villanueva MR, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, et al. Efficacy, safety, and regulation of Cannabidiol on Chronic Pain: A systematic review. Cureus. 2022; doi:10.7759/cureus.26913
71. Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, et al. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: A systematic review and meta-analyses. Pain. 2021;163(4):610–36. doi:10.1097/j.pain.0000000000002423
72. van de Kooij P. Comments on the efficacy and safety of opioidanalgesics for the management of chronic lowback pain. Pain Physician. 2021; doi:10.36076/ppj.2021/24/e377

73. Mekhail N, Eldabe S, Templeton E, Costandi S, Rosenquist R. Pain management interventions for the treatment of chronic low back pain. The Clinical Journal of Pain. 2023;39(7):349–64. doi:10.1097/ajp.0000000000001116
74. Tucker-Bartley A, Selen DJ, Golden E, van Gool R, Ebb D, Mannstadt M, et al. Pharmacological interventions targeting pain in fibrous dysplasia/McCune–Albright syndrome. International Journal of Molecular Sciences. 2023;24(3):2550. doi:10.3390/ijms24032550
75. Davies A. Interventional Pain Management and chronic low back pain: Effectiveness and patient outcomes. American Journal of Biomedical Science & Research. 2022;15(5):575–80. doi:10.34297/ajbsr.2022.15.002156
76. Schemer L, Rief W, Glombiewski JA. <P>treatment expectations towards different pain management approaches: Two perspectives</p>. Journal of Pain Research. 2020;Volume 13:1725–36. doi:10.2147/jpr.s247177
77. Petelin DS, Istomina NS, Tsapko DS, Magomedov AA, Bezrukov VE, Kochergina MS, et al. Approaches to psychotherapy for chronic musculoskeletal pain. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):68–73. doi:10.14412/2074-2711-2022-3-68-73
78. Smith TE. Interventional treatment of chronic pain. Chronic Pain Management in General and Hospital Practice. 2020;113–28. doi:10.1007/978-981-15-2933-7_7
79. Cheville AL, Basford JR. Rehabilitation medicine approaches to pain management. Oxford Textbook of Palliative Medicine. 2015;606–13. doi:10.1093/med/9780199656097.003.0910
80. Aravagiri K, Ali A, Wang HC, Candido KD, Knezevic NN. Identifying molecular mechanisms of acute to chronic pain transition and potential drug targets. Expert Opinion on Therapeutic Targets. 2022;26(9):801–10. doi:10.1080/14728222.2022.2137404
81. Bernatoniene J, Sciupokas A, Kopustinskiene DM, Petrikonis K. Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics. 2023;15(7):1799. doi:10.3390/pharmaceutics15071799
82. Obeng S, Hiranita T, León F, McMahon LR, McCurdy CR. Novel approaches, drug candidates, and targets in Pain drug discovery. Journal of Medicinal Chemistry. 2021;64(10):6523–48. doi:10.1021/acs.jmedchem.1c00028
83. Sisignano M, Parnham MJ, Geisslinger G. Novel approaches to persistent pain therapy. Trends in Pharmacological Sciences. 2019;40(6):367–77. doi:10.1016/j.tips.2019.04.003
84. Auyeung A, Wang HC, Aravagiri K, Knezevic NN. Kynurenine pathway metabolites as potential biomarkers in chronic pain. Pharmaceuticals. 2023;16(5):681. doi:10.3390/ph16050681
85. Eldabe S, Obara I, Panwar C, Caraway D. Biomarkers for chronic pain: Significance and summary of recent advances. Pain Research and Management. 2022;2022:1–6. doi:10.1155/2022/1940906
86. Morales AG, Lee JJ, Caliva F, Iriondo C, Liu F, Majumdar S, et al. Uncovering associations between data-driven learned QMRI biomarkers and chronic pain. Scientific Reports. 2021;11(1). doi:10.1038/s41598-021-01111-x
87. Zhang Z, Gewandter JS, Geha P. Brain imaging biomarkers for chronic pain. Frontiers in Neurology. 2022;12. doi:10.3389/fneur.2021.734821

88. Karimian F, Saadat S, Hosseininezhad M. Chronic pain and psychological interventions: A systematic review. Iranian Journal of Neurosurgery. 2023;9(0):6–6. doi:10.32598/irjns.9.8
89. Morris JR, Harrison SL, Robinson J, Martin D, Avery L. Non-pharmacological and non-invasive interventions for chronic pain in people with chronic obstructive pulmonary disease: A systematic review without meta-analysis. Respiratory Medicine. 2023;211:107191. doi:10.1016/j.rmed.2023.107191
90. Mekhail N, Eldabe S, Templeton E, Costandi S, Rosenquist R. Pain management interventions for the treatment of chronic low back pain. The Clinical Journal of Pain. 2023;39(7):349–64. doi:10.1097/ajp.0000000000001116
91. Peters M. Can perioperative psychological interventions reduce chronic pain after surgery? British Journal of Hospital Medicine. 2023;84(5):1–8. doi:10.12968/hmed.2022.0400.

HOW TO CITE: Abel sabu, Viresh. k. chandur, A R Shabaraya A Comprehensive Review of Pharmacological Interventions for Chronic Pain, Int. J. in Pharm. Sci., 2023, Vol 1, Issue 11, 527-541. https://doi.org/ 10.5281/zenodo.10207390